| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Erectile Dysfunction | 12 | 2024 | 76 | 7.430 |
Why?
|
| Penile Implantation | 9 | 2024 | 14 | 6.300 |
Why?
|
| Penile Prosthesis | 10 | 2024 | 25 | 6.080 |
Why?
|
| Hypogonadism | 7 | 2024 | 40 | 3.850 |
Why?
|
| Penis | 11 | 2025 | 61 | 3.410 |
Why?
|
| Testosterone | 6 | 2024 | 273 | 2.440 |
Why?
|
| Penile Diseases | 4 | 2022 | 8 | 2.250 |
Why?
|
| Penile Induration | 4 | 2025 | 8 | 2.040 |
Why?
|
| Prostatic Hyperplasia | 4 | 2023 | 91 | 1.910 |
Why?
|
| Urologic Diseases | 3 | 2023 | 42 | 1.890 |
Why?
|
| Male | 79 | 2025 | 43925 | 1.700 |
Why?
|
| Infertility, Male | 3 | 2023 | 26 | 1.650 |
Why?
|
| Quality of Life | 7 | 2023 | 1744 | 1.310 |
Why?
|
| Humans | 90 | 2025 | 92337 | 1.270 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 743 | 1.210 |
Why?
|
| Hormone Replacement Therapy | 3 | 2024 | 93 | 1.190 |
Why?
|
| Prostatectomy | 8 | 2022 | 479 | 1.130 |
Why?
|
| Lower Urinary Tract Symptoms | 2 | 2021 | 76 | 1.110 |
Why?
|
| Organ Transplantation | 2 | 2021 | 288 | 1.100 |
Why?
|
| Urolithiasis | 2 | 2017 | 4 | 1.040 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2019 | 343 | 1.030 |
Why?
|
| Kidney Neoplasms | 10 | 2019 | 530 | 1.020 |
Why?
|
| Hyaluronic Acid | 2 | 2025 | 52 | 1.020 |
Why?
|
| Prostatic Neoplasms | 7 | 2021 | 1771 | 1.000 |
Why?
|
| Orchiectomy | 2 | 2024 | 62 | 0.980 |
Why?
|
| Nephrectomy | 12 | 2019 | 294 | 0.970 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2022 | 73 | 0.930 |
Why?
|
| Suture Techniques | 2 | 2024 | 144 | 0.920 |
Why?
|
| Testicular Neoplasms | 2 | 2024 | 120 | 0.910 |
Why?
|
| Cachexia | 1 | 2024 | 13 | 0.910 |
Why?
|
| Urinary Bladder | 3 | 2017 | 250 | 0.900 |
Why?
|
| Sperm Retrieval | 1 | 2024 | 3 | 0.890 |
Why?
|
| Fertility Preservation | 1 | 2024 | 20 | 0.860 |
Why?
|
| Semen | 1 | 2023 | 14 | 0.860 |
Why?
|
| Penile Neoplasms | 1 | 2023 | 17 | 0.850 |
Why?
|
| Vasectomy | 1 | 2023 | 4 | 0.850 |
Why?
|
| Urinary Sphincter, Artificial | 2 | 2020 | 14 | 0.840 |
Why?
|
| Exosomes | 1 | 2023 | 57 | 0.810 |
Why?
|
| Penile Erection | 4 | 2023 | 22 | 0.790 |
Why?
|
| Postoperative Complications | 10 | 2024 | 2458 | 0.770 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2021 | 10 | 0.750 |
Why?
|
| Premature Ejaculation | 1 | 2021 | 1 | 0.740 |
Why?
|
| Telemedicine | 2 | 2024 | 213 | 0.740 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2020 | 374 | 0.720 |
Why?
|
| Urinary Incontinence, Stress | 2 | 2020 | 198 | 0.720 |
Why?
|
| Genitalia | 1 | 2021 | 21 | 0.720 |
Why?
|
| Hyperthyroidism | 1 | 2021 | 76 | 0.710 |
Why?
|
| Mycophenolic Acid | 2 | 2011 | 85 | 0.710 |
Why?
|
| Urinary Tract | 1 | 2021 | 35 | 0.690 |
Why?
|
| Extracorporeal Shockwave Therapy | 1 | 2020 | 2 | 0.690 |
Why?
|
| Transgender Persons | 1 | 2022 | 116 | 0.690 |
Why?
|
| Vaping | 1 | 2021 | 46 | 0.680 |
Why?
|
| Urinary Incontinence | 1 | 2022 | 216 | 0.670 |
Why?
|
| Thrombosis | 2 | 2021 | 312 | 0.660 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2021 | 74 | 0.660 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2020 | 27 | 0.650 |
Why?
|
| Sexual and Gender Minorities | 1 | 2023 | 228 | 0.630 |
Why?
|
| Chronic Pain | 2 | 2024 | 171 | 0.620 |
Why?
|
| Self-Injurious Behavior | 1 | 2021 | 114 | 0.600 |
Why?
|
| Retrospective Studies | 23 | 2024 | 9703 | 0.590 |
Why?
|
| Middle Aged | 31 | 2024 | 27030 | 0.590 |
Why?
|
| Treatment Outcome | 16 | 2024 | 8740 | 0.570 |
Why?
|
| Cystocele | 1 | 2016 | 7 | 0.540 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 989 | 0.530 |
Why?
|
| Kidney Transplantation | 3 | 2013 | 863 | 0.510 |
Why?
|
| Allografts | 1 | 2016 | 197 | 0.500 |
Why?
|
| Skin Transplantation | 1 | 2016 | 192 | 0.490 |
Why?
|
| Vagina | 1 | 2016 | 176 | 0.480 |
Why?
|
| Music Therapy | 1 | 2015 | 2 | 0.480 |
Why?
|
| Aged | 25 | 2023 | 19943 | 0.480 |
Why?
|
| Cystoscopy | 1 | 2015 | 37 | 0.470 |
Why?
|
| Female | 32 | 2023 | 47893 | 0.470 |
Why?
|
| Health Care Costs | 1 | 2017 | 248 | 0.470 |
Why?
|
| Edema | 1 | 2014 | 68 | 0.460 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 48 | 0.450 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 81 | 0.450 |
Why?
|
| Kidney | 3 | 2019 | 1145 | 0.440 |
Why?
|
| Urology | 4 | 2020 | 125 | 0.430 |
Why?
|
| Adult | 21 | 2024 | 27532 | 0.430 |
Why?
|
| Drainage | 1 | 2014 | 169 | 0.430 |
Why?
|
| Bone Neoplasms | 2 | 2014 | 313 | 0.430 |
Why?
|
| Prospective Studies | 6 | 2023 | 4468 | 0.420 |
Why?
|
| Fertility | 2 | 2023 | 116 | 0.410 |
Why?
|
| Arthritis, Reactive | 1 | 2012 | 2 | 0.400 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 33 | 0.400 |
Why?
|
| Anxiety | 1 | 2015 | 324 | 0.400 |
Why?
|
| Urography | 1 | 2012 | 41 | 0.400 |
Why?
|
| Renal Veins | 2 | 2013 | 29 | 0.400 |
Why?
|
| Analgesics, Opioid | 2 | 2016 | 472 | 0.390 |
Why?
|
| Pain | 1 | 2015 | 406 | 0.390 |
Why?
|
| Robotic Surgical Procedures | 4 | 2020 | 342 | 0.390 |
Why?
|
| Obesity | 3 | 2020 | 1016 | 0.390 |
Why?
|
| BCG Vaccine | 1 | 2012 | 35 | 0.390 |
Why?
|
| Hematuria | 1 | 2012 | 50 | 0.380 |
Why?
|
| Prevalence | 4 | 2021 | 1294 | 0.380 |
Why?
|
| Guanine | 1 | 2013 | 207 | 0.380 |
Why?
|
| Osteolysis | 1 | 2011 | 14 | 0.380 |
Why?
|
| Nephrolithiasis | 1 | 2012 | 25 | 0.380 |
Why?
|
| Prosthesis Failure | 2 | 2024 | 118 | 0.380 |
Why?
|
| Femoral Neoplasms | 1 | 2011 | 19 | 0.370 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 74 | 0.370 |
Why?
|
| Lateral Ligament, Ankle | 1 | 2011 | 1 | 0.370 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 35 | 0.370 |
Why?
|
| Laparoscopy | 5 | 2019 | 785 | 0.370 |
Why?
|
| Adjuvants, Immunologic | 1 | 2012 | 169 | 0.370 |
Why?
|
| Motor Activity | 1 | 2014 | 330 | 0.370 |
Why?
|
| Osteoblasts | 1 | 2011 | 98 | 0.360 |
Why?
|
| Ankle | 1 | 2011 | 24 | 0.360 |
Why?
|
| Femur | 1 | 2011 | 107 | 0.360 |
Why?
|
| Transplantation Immunology | 1 | 2011 | 83 | 0.350 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2012 | 154 | 0.350 |
Why?
|
| Azathioprine | 1 | 2011 | 124 | 0.350 |
Why?
|
| Diet | 1 | 2014 | 448 | 0.350 |
Why?
|
| Graft Survival | 2 | 2011 | 935 | 0.340 |
Why?
|
| HIV Infections | 3 | 2017 | 895 | 0.340 |
Why?
|
| Length of Stay | 6 | 2020 | 798 | 0.340 |
Why?
|
| Urinary Fistula | 1 | 2009 | 7 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 502 | 0.330 |
Why?
|
| Rectal Fistula | 1 | 2009 | 18 | 0.330 |
Why?
|
| Prosthesis-Related Infections | 2 | 2020 | 56 | 0.330 |
Why?
|
| Cadaver | 5 | 2012 | 191 | 0.320 |
Why?
|
| Antiviral Agents | 1 | 2013 | 497 | 0.310 |
Why?
|
| Urethra | 2 | 2020 | 114 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 2680 | 0.310 |
Why?
|
| Androgen Antagonists | 3 | 2021 | 139 | 0.280 |
Why?
|
| Renal Artery | 1 | 2007 | 50 | 0.270 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 416 | 0.270 |
Why?
|
| Men's Health | 2 | 2024 | 6 | 0.270 |
Why?
|
| Ureteroscopy | 2 | 2017 | 38 | 0.260 |
Why?
|
| Lithotripsy | 2 | 2017 | 45 | 0.250 |
Why?
|
| Knee Joint | 1 | 2007 | 162 | 0.250 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2729 | 0.250 |
Why?
|
| Cohort Studies | 6 | 2020 | 2978 | 0.250 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 267 | 0.250 |
Why?
|
| United States | 5 | 2023 | 7348 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 3775 | 0.240 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 34 | 0.230 |
Why?
|
| Vas Deferens | 1 | 2024 | 8 | 0.230 |
Why?
|
| Testicular Diseases | 1 | 2024 | 9 | 0.230 |
Why?
|
| Spermatic Cord | 1 | 2024 | 6 | 0.220 |
Why?
|
| Denervation | 1 | 2024 | 24 | 0.220 |
Why?
|
| Pain Measurement | 2 | 2016 | 360 | 0.220 |
Why?
|
| Seminoma | 1 | 2024 | 14 | 0.220 |
Why?
|
| Spermatogonia | 1 | 2023 | 13 | 0.220 |
Why?
|
| Adolescent | 6 | 2023 | 9504 | 0.220 |
Why?
|
| Cryopreservation | 1 | 2024 | 72 | 0.220 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2023 | 17 | 0.210 |
Why?
|
| Risk Factors | 8 | 2020 | 5704 | 0.210 |
Why?
|
| California | 2 | 2015 | 156 | 0.210 |
Why?
|
| Maternal Age | 1 | 2023 | 46 | 0.210 |
Why?
|
| Robotics | 2 | 2019 | 269 | 0.210 |
Why?
|
| Demography | 2 | 2015 | 186 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 1091 | 0.200 |
Why?
|
| Gels | 1 | 2022 | 52 | 0.200 |
Why?
|
| Esthetics | 1 | 2022 | 49 | 0.200 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1119 | 0.200 |
Why?
|
| Gender Identity | 1 | 2022 | 54 | 0.200 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 67 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 6916 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2023 | 172 | 0.190 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2012 | 41 | 0.190 |
Why?
|
| Syndrome | 1 | 2022 | 449 | 0.190 |
Why?
|
| Kidney Calculi | 2 | 2015 | 343 | 0.190 |
Why?
|
| North America | 2 | 2024 | 188 | 0.190 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 807 | 0.190 |
Why?
|
| Ejaculation | 1 | 2021 | 9 | 0.190 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 341 | 0.180 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2021 | 34 | 0.180 |
Why?
|
| Aromatase Inhibitors | 1 | 2021 | 30 | 0.180 |
Why?
|
| Endoscopy | 2 | 2017 | 363 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2024 | 963 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 358 | 0.180 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2021 | 36 | 0.170 |
Why?
|
| Ireland | 2 | 2011 | 9 | 0.170 |
Why?
|
| Surgical Flaps | 1 | 2022 | 254 | 0.170 |
Why?
|
| Patient Discharge | 2 | 2020 | 339 | 0.170 |
Why?
|
| Urethral Stricture | 1 | 2020 | 14 | 0.170 |
Why?
|
| Fibrosis | 1 | 2021 | 239 | 0.170 |
Why?
|
| Urinary Retention | 1 | 2020 | 43 | 0.160 |
Why?
|
| Dissection | 2 | 2011 | 43 | 0.160 |
Why?
|
| Medicare | 1 | 2023 | 440 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2019 | 24 | 0.160 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2020 | 15 | 0.160 |
Why?
|
| Abdominal Injuries | 1 | 2019 | 51 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1398 | 0.160 |
Why?
|
| Patient Satisfaction | 1 | 2023 | 505 | 0.160 |
Why?
|
| Genitalia, Male | 1 | 2019 | 24 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2021 | 708 | 0.150 |
Why?
|
| Priapism | 1 | 2018 | 5 | 0.150 |
Why?
|
| Cannabis | 1 | 2019 | 35 | 0.150 |
Why?
|
| Prosthesis Implantation | 1 | 2020 | 130 | 0.150 |
Why?
|
| Mortality | 1 | 2019 | 150 | 0.150 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 1181 | 0.150 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2019 | 115 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 75 | 0.140 |
Why?
|
| Nephrolithotomy, Percutaneous | 1 | 2017 | 8 | 0.140 |
Why?
|
| Specialization | 1 | 2017 | 69 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2020 | 224 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2018 | 900 | 0.140 |
Why?
|
| Empyema | 1 | 2017 | 9 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 2035 | 0.140 |
Why?
|
| Operative Time | 4 | 2020 | 158 | 0.140 |
Why?
|
| Asia | 1 | 2017 | 102 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 390 | 0.140 |
Why?
|
| Australia | 1 | 2017 | 102 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 340 | 0.140 |
Why?
|
| Urinary Bladder Diseases | 1 | 2017 | 40 | 0.130 |
Why?
|
| Animals | 5 | 2023 | 28003 | 0.130 |
Why?
|
| Endocrinology | 1 | 2017 | 50 | 0.130 |
Why?
|
| Solvents | 1 | 2016 | 90 | 0.130 |
Why?
|
| Ischemia | 1 | 2018 | 254 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 866 | 0.130 |
Why?
|
| Europe | 1 | 2017 | 328 | 0.130 |
Why?
|
| Mice | 3 | 2023 | 12110 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2016 | 2369 | 0.130 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 46 | 0.130 |
Why?
|
| Cryosurgery | 1 | 2016 | 60 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2017 | 239 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 996 | 0.120 |
Why?
|
| Age Factors | 3 | 2016 | 1905 | 0.120 |
Why?
|
| Morbidity | 3 | 2020 | 157 | 0.120 |
Why?
|
| Young Adult | 3 | 2023 | 6624 | 0.120 |
Why?
|
| Graft Rejection | 2 | 2011 | 1110 | 0.120 |
Why?
|
| Bacteriuria | 1 | 2014 | 9 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2019 | 955 | 0.120 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 64 | 0.120 |
Why?
|
| Family Health | 1 | 2015 | 158 | 0.120 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2014 | 30 | 0.120 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 55 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 159 | 0.120 |
Why?
|
| Leiomyosarcoma | 1 | 2015 | 46 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 162 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2014 | 35 | 0.110 |
Why?
|
| Logistic Models | 2 | 2015 | 1239 | 0.110 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 54 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 52 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2015 | 134 | 0.110 |
Why?
|
| Veterans | 1 | 2015 | 89 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2012 | 1240 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2017 | 362 | 0.110 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2014 | 12 | 0.110 |
Why?
|
| Recurrence | 1 | 2017 | 1180 | 0.110 |
Why?
|
| Rats | 1 | 2020 | 4067 | 0.110 |
Why?
|
| Fever | 1 | 2014 | 130 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 595 | 0.110 |
Why?
|
| Skin | 1 | 2016 | 594 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 498 | 0.100 |
Why?
|
| Lamivudine | 1 | 2013 | 13 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 871 | 0.100 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 47 | 0.100 |
Why?
|
| Pelvis | 1 | 2013 | 96 | 0.100 |
Why?
|
| Virus Activation | 1 | 2013 | 42 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 795 | 0.100 |
Why?
|
| Medicaid | 1 | 2015 | 248 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 490 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 619 | 0.100 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2012 | 15 | 0.100 |
Why?
|
| Chloride Channels | 1 | 2012 | 42 | 0.100 |
Why?
|
| Pyrroles | 1 | 2013 | 171 | 0.090 |
Why?
|
| Vena Cava, Inferior | 1 | 2013 | 140 | 0.090 |
Why?
|
| Rupture | 1 | 2011 | 59 | 0.090 |
Why?
|
| Cystostomy | 1 | 2011 | 15 | 0.090 |
Why?
|
| Peritoneum | 1 | 2011 | 57 | 0.090 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 26 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 225 | 0.090 |
Why?
|
| X-Ray Microtomography | 1 | 2011 | 95 | 0.090 |
Why?
|
| Survival Rate | 2 | 2015 | 1927 | 0.090 |
Why?
|
| Thrombectomy | 1 | 2013 | 197 | 0.090 |
Why?
|
| Indoles | 1 | 2013 | 306 | 0.090 |
Why?
|
| Mice, SCID | 1 | 2011 | 265 | 0.090 |
Why?
|
| Heart Atria | 1 | 2013 | 289 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2011 | 120 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 569 | 0.090 |
Why?
|
| Sepsis | 1 | 2014 | 350 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 253 | 0.090 |
Why?
|
| Urologic Surgical Procedures | 1 | 2012 | 150 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2011 | 241 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2013 | 308 | 0.080 |
Why?
|
| Osteoporotic Fractures | 1 | 2011 | 51 | 0.080 |
Why?
|
| Child | 3 | 2011 | 7334 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2011 | 124 | 0.080 |
Why?
|
| Postoperative Care | 1 | 2011 | 239 | 0.080 |
Why?
|
| Trauma Severity Indices | 2 | 2019 | 46 | 0.080 |
Why?
|
| Plant Extracts | 1 | 2011 | 245 | 0.080 |
Why?
|
| Neoplasms | 1 | 2024 | 3117 | 0.080 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 2669 | 0.080 |
Why?
|
| Ependymoma | 1 | 2009 | 24 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 538 | 0.070 |
Why?
|
| Spinal Neoplasms | 1 | 2009 | 78 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2012 | 677 | 0.070 |
Why?
|
| Cystectomy | 2 | 2020 | 114 | 0.070 |
Why?
|
| Tendon Injuries | 1 | 2007 | 38 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2448 | 0.070 |
Why?
|
| Infant | 2 | 2011 | 3218 | 0.070 |
Why?
|
| Menisci, Tibial | 1 | 2007 | 26 | 0.070 |
Why?
|
| Blood Transfusion | 2 | 2019 | 168 | 0.070 |
Why?
|
| Ligaments, Articular | 1 | 2007 | 41 | 0.070 |
Why?
|
| Tendons | 1 | 2007 | 49 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2011 | 3818 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1477 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1310 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1592 | 0.060 |
Why?
|
| Wound Healing | 1 | 2007 | 373 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1919 | 0.060 |
Why?
|
| Hypospadias | 1 | 2024 | 7 | 0.060 |
Why?
|
| Ligation | 1 | 2024 | 55 | 0.060 |
Why?
|
| Blood Loss, Surgical | 2 | 2016 | 122 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2019 | 393 | 0.050 |
Why?
|
| Comorbidity | 2 | 2019 | 987 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 1576 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 800 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2368 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 3509 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2024 | 320 | 0.050 |
Why?
|
| Mutation | 1 | 2012 | 4204 | 0.040 |
Why?
|
| Pain, Postoperative | 2 | 2013 | 275 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 2794 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 98 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 106 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 165 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 160 | 0.040 |
Why?
|
| Patient Simulation | 1 | 2018 | 42 | 0.040 |
Why?
|
| Intraoperative Complications | 1 | 2019 | 190 | 0.040 |
Why?
|
| Anuria | 1 | 2017 | 6 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 2017 | 61 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 283 | 0.030 |
Why?
|
| Urinary Diversion | 1 | 2017 | 44 | 0.030 |
Why?
|
| Reoperation | 1 | 2019 | 654 | 0.030 |
Why?
|
| Coronary Thrombosis | 1 | 2016 | 16 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2016 | 27 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2018 | 235 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 331 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 800 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1511 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2019 | 473 | 0.030 |
Why?
|
| Aspirin | 1 | 2016 | 163 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 314 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2014 | 13 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 155 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 229 | 0.030 |
Why?
|
| Anilides | 1 | 2014 | 45 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 107 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 411 | 0.030 |
Why?
|
| Nitriles | 1 | 2014 | 158 | 0.030 |
Why?
|
| Curriculum | 1 | 2018 | 581 | 0.030 |
Why?
|
| Lymphocele | 1 | 2013 | 6 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 70 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1194 | 0.020 |
Why?
|
| Anoctamins | 1 | 2012 | 1 | 0.020 |
Why?
|
| Finland | 1 | 2012 | 29 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2012 | 53 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 160 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2012 | 87 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 1503 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 311 | 0.020 |
Why?
|
| Serenoa | 1 | 2011 | 1 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1733 | 0.020 |
Why?
|
| Rectum | 1 | 2012 | 149 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2012 | 64 | 0.020 |
Why?
|
| Acidosis | 1 | 2011 | 55 | 0.020 |
Why?
|
| Abdomen | 1 | 2012 | 125 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 288 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 307 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 810 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 498 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 332 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 5430 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 106 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 891 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2012 | 224 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 795 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2011 | 136 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 800 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 968 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 552 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 689 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 598 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 128 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 474 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 3872 | 0.020 |
Why?
|
| World Health Organization | 1 | 2009 | 114 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1661 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 284 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2012 | 550 | 0.020 |
Why?
|
| Sutures | 1 | 2007 | 60 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2007 | 85 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 1863 | 0.020 |
Why?
|
| Random Allocation | 1 | 2007 | 328 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 438 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 612 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 1308 | 0.020 |
Why?
|
| Swine | 1 | 2007 | 605 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 2498 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2012 | 1392 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 1312 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1807 | 0.010 |
Why?
|